All In Biotech

Drug Trial Radar · NCT05834543

Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

34

Actual

Start

May 26, 2023

Primary completion

Oct 23, 2024

Study completion Mar 3, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the efficacy and safety of TQB2618 injection combined Penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic esophageal squamous cell carcinoma compared with Penpulimab combined chemotherapy. The primary efficacy outcomes are progression free survival (PFS) and objective response rate (ORR).

Conditions

  • Advanced Esophageal Squamous Cell Carcinoma

Interventions

  • TQB2618 injection, Penpulimab injection, Paclitaxel, CisplatinDrug

    TQB2618 injection:Anti-TIM-3 monoclonal antibody. Penpulimab injection:Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1). Paclitaxel and Cisplatin are chemotherapy.

  • Penpulimab injection, Paclitaxel, CisplatinDrug

    Penpulimab injection:Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1). Paclitaxel and Cisplatin are chemotherapy.

  • TQB2618 injection, Penpulimab injection, TQB3617capsulesDrug

    TQB2618 injection:Anti-TIM-3 monoclonal antibody. Penpulimab injection:Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: Baseline up to two years.
  2. ORRTime frame: Baseline up to two years.

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Tongling People's Hospital

    Tongling, Anhui, China

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • AnYang Tumor Hospital

    Anyang, Henan, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Zhumadian Central Hospital

    Zhumadian, Henan, China

  • Affiliated Hospital of Jining Medical College

    Jining, Shandong, China

  • Changzhi People's Hospital

    Changzhi, Shanxi, China

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, Shanxi, China

  • Jincheng General Hospital

    Jincheng, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.